ITEM VIEW

Ovarian germ cell tumour and bleomycin-induced lung injury

dc.contributor.authorBarnardt, P.en_ZA
dc.contributor.authorGriffith-Richards, S.en_ZA
dc.date.accessioned2020-02-10T07:36:20Z
dc.date.available2020-02-10T07:36:20Z
dc.date.issued2018
dc.identifier.citationBarnardt, P. & Griffith-Richards, S. 2018. Ovarian germ cell tumour and bleomycin-induced lung injury. Southern African Journal of Gynaecological Oncology, 10(2):30-33, doi:10.1080/20742835.2018.1479213
dc.identifier.issn2220-105X (online)
dc.identifier.issn2074-2835 (print)
dc.identifier.otherdoi:10.1080/20742835.2018.1479213
dc.identifier.urihttp://hdl.handle.net/10019.1/107455
dc.descriptionCITATION: Barnardt, P. & Griffith-Richards, S. 2018. Ovarian germ cell tumour and bleomycin-induced lung injury. Southern African Journal of Gynaecological Oncology, 10(2):30-33, doi:10.1080/20742835.2018.1479213.
dc.descriptionThe original publication is available at https://www.tandfonline.com
dc.description.abstractBleomycin, an antibiotic agent with antitumour activity, is an important drug in the management of many oncological malignancies such as lymphoma and germ cell tumours. These tumours are potentially curable and mostly affect young people. The potential side effects and long-term toxicities should be considered. The major limitation of bleomycin therapy is pulmonary toxicity and may be life threatening in about 10% of cases. This article reports a case of an ovarian mixed germ cell tumour, which presented with bleomycin-associated pulmonary toxicity.en_ZA
dc.description.urihttps://www.tandfonline.com/doi/full/10.1080/20742835.2018.1479213
dc.format.extent4 pages
dc.language.isoen_ZAen_ZA
dc.publisherMedpharm Publications
dc.subjectBleomycinen_ZA
dc.titleOvarian germ cell tumour and bleomycin-induced lung injuryen_ZA
dc.typeArticleen_ZA
dc.description.versionPublisher's version
dc.rights.holderAuthors retain copyright


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

ITEM VIEW